IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading information regarding its growth potential and operational capabilities during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 of fiscal 2024 on July 25, 2024, and subsequently reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance of its iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [4]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [4]. Legal Context - The class action lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply to be appointed as lead plaintiff [1]. - The lawsuit claims that the company made overwhelmingly positive statements while concealing material adverse facts about its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [5].